12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Company News  |  Deals

PanOptica, Astellas deal

Astellas' OSI Pharmaceuticals Inc. subsidiary granted PanOptica exclusive, worldwide rights to develop and commercialize PAN-90806 for ophthalmic indications. The small...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >